The role of apolipoprotein A5 in non-alcoholic fatty liver disease

Gut

Volumn 60, Issue 7, 2011, Pages 985-991

  Ress, C ^a   Moschen, A R ^a   Sausgruber, N ^a   Tschoner, A ^a   Graziadei, I ^a   Weiss, H ^b   Schgoer, W ^a   Ebenbichler, C F ^a   Konrad, R J ^c   Patsch, J R ^a   Tilg, H ^a   Kaser, Susanne ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Department of Surgery   (Austria)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; CARNITINE PALMITOYLTRANSFERASE I; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID SYNTHASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BARIATRIC SURGERY; CELL CULTURE; CELL LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID STORAGE; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WEIGHT REDUCTION;

ADULT; ANTHROPOMETRY; APOLIPOPROTEINS A; BARIATRIC SURGERY; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; OBESITY; PPAR GAMMA; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION; TRIGLYCERIDES; TUMOR CELLS, CULTURED; WEIGHT LOSS;

EID: 79958212809     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.222224     Document Type: Article

References (46)

1. Hjelkrem MC, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Minerva Med 2008;99:583-93.
2. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6. (Pubitemid 44307393)
3. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48:S104-12.
4. Schreuder TC, Verwer BJ, van Nieuwkerk CM, et al. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008;14:2474-86. (Pubitemid 352037734)
5. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008;34:643-8.
6. Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract 2010;64:968-83.
7. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73. (Pubitemid 32952971)
8. van der Vliet HN, Sammels MG, Leegwater AC, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001;276:44512-20.
9. Hahne P, Krempler F, Schaap FG, et al. Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med 2008;264:452-62.
10. Jakel H, Nowak M, Moitrot E, et al. The liver X receptor ligand T0901317 downregulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004;279:45462-9. (Pubitemid 39491531)
11. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003;278:25468-80. (Pubitemid 36835298)
12. Ishihara M, Kujiraoka T, Iwasaki T, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 2005;46:2015-22. (Pubitemid 41248499)
13. O'Brien PJ, Alborn WE, Sloan JH, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005;51:351-9. (Pubitemid 40175805)
14. van der Vliet HN, Schaap FG, Levels JH, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002;295:1156-9.
15. Henneman P, Schaap FG, Havekes LM, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 2007;193:129-34. (Pubitemid 46776694)
16. Huang XS, Zhao SP, Zhang Q, et al. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis 2009;204:e99-102.
17. Hyun YJ, Jang Y, Chae JS, et al. Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis 2009;205:568-73.
18. Wang J, Ban MR, Kennedy BA, et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008;5:730-7.
19. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9.
20. Merkel M, Loeffler B, Kluger M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005;280:21553-60. (Pubitemid 40805722)
21. Schaap FG, Rensen PC, Voshol PJ, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-7. (Pubitemid 38900062)
22. Shu X, Chan J, Ryan RO, et al. Apolipoprotein A-V association with intracellular lipid droplets. J Lipid Res 2007;48:1445-50. (Pubitemid 47312006)
23. Shu X, Nelbach L, Ryan RO, et al. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation. Biochim Biophys Acta 2010;1801:605-8.
24. Ebenbichler CF, Laimer M, Kaser S, et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol 2002;22:1465-9.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19. (Pubitemid 15018832)
26. Moschen AR, Molnar C, Wolf AM, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009;51:765-77.
27. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
28. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
29. Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
30. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol 2009;43:970-4.
31. Nowak M, Helleboid-Chapman A, Jakel H, et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 2005;25:1537-48. (Pubitemid 40204928)
32. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A 1998;95:13018-23. (Pubitemid 28509516)
33. Linden D, William-Olsson L, Ahnmark A, et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 2006;20:434-43. (Pubitemid 44933320)
34. Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007;282:22678-88. (Pubitemid 47267336)
35. Rufer AC, Thoma R, Hennig M. Structural insight into function and regulation of carnitine palmitoyltransferase. Cell Mol Life Sci 2009;66:2489-501.
36. Stefanovic-Racic M, Perdomo G, Mantell BS, et al. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008;294:E969-77.
37. Zieleniak A, Wojcik M, Wozniak LA. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) 2008;56:331-45.
38. Oakes ND, Kennedy CJ, Jenkins AB, et al. A new antidiabetic agent, BRL 49 653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994;43:1203-10.
39. Cantello BC, Cawthorne MA, Cottam GP, et al. [[omega-(Heterocyclylamino) alkoxy] benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 1994;37:3977-85.
40. Sohda T, Momose Y, Meguro K, et al. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4- thiazolidinediones. Arzneimittelforschung 1990;40:37-42.
41. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307. (Pubitemid 44837778)
42. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-74. (Pubitemid 46918320)
43. Yu XX, Murray SF, Pandey SK, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005;42:362-71. (Pubitemid 41061089)
44. Shindo N, Fujisawa T, Sugimoto K, et al. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol 2010;52:903-12.
45. Pan X, Hussain FN, Iqbal J, et al. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem 2007;282:17078-89. (Pubitemid 47093224)
46. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr Pharm Des 2010;16:1893-5.